Zevaquenabant

Zevaquenabant (also known as JNJ-42165279) is a drug that is currently under development by Janssen Pharmaceuticals. It is being investigated for its potential use in the treatment of mood disorders and addictive disorders. Zevaquenabant is a cannabinoid receptor type 2 (CB2) antagonist.

History

Zevaquenabant was first developed by Janssen Pharmaceuticals, a Belgium-based pharmaceutical company. The drug is currently in the clinical trial phase, with studies focusing on its potential use in the treatment of mood and addictive disorders.

Mechanism of Action

Zevaquenabant works by blocking the CB2 receptors in the brain. These receptors are part of the endocannabinoid system, which plays a role in a variety of physiological processes including pain sensation, mood, and memory. By blocking these receptors, Zevaquenabant may help to reduce the symptoms associated with mood and addictive disorders.

Clinical Trials

As of 2021, Zevaquenabant is in the clinical trial phase. These trials are investigating the drug's safety, efficacy, and optimal dosage. The results of these trials will determine whether Zevaquenabant is approved for use in the treatment of mood and addictive disorders.

Potential Uses

If approved, Zevaquenabant could be used in the treatment of a variety of mood disorders, including depression and anxiety. It could also be used in the treatment of addictive disorders, such as substance abuse and gambling addiction.

See Also

• Cannabinoid receptor antagonist
• Janssen Pharmaceuticals
• Clinical trial

References

Zevaquenabant Resources
Need Help Finding a Doctor? Need help finding a doctor or specialist anywhere in the world? Explore our world directory. WikiMD's DocFinder can assist you in locating millions of physicians.	Medical Knowledge Access the latest research - Most recent articles Ongoing trials.